Serum sodium predicts mortality in patients listed for liver transplantation

With the implementation of the model for end‐stage liver disease (MELD), refractory ascites, a known predictor of mortality in cirrhosis, was removed as a criterion for liver allocation. Because ascites is associated with low serum sodium, we evaluated serum sodium as an independent predictor of mortality in patients with cirrhosis who were listed for liver transplantation and whether the addition of serum sodium to MELD was superior to MELD alone. This is a single‐center retrospective cohort of all adult patients with cirrhosis listed for transplantation from February 27, 2002, to December 26, 2003. Listing laboratories were those nearest the listing date ±2 months. Of the 513 patients meeting inclusion criteria, 341 were still listed, while 172 were removed from the list (105 for transplantation, 56 for death, 11 for other reasons). The median serum sodium and MELD scores were 137 mEq/L (range, 110‐155) and 15 (range, 6‐51), respectively, at listing. Median follow‐up was 201 (range, 1‐662) days. The risk of death with serum sodium < 126 mEq/L at listing or while listed was increased, with hazard ratios of 7.8 (P < .001) and 6.3 (P < .001), respectively, and the association was independent of MELD. The c‐statistics of receiver operating characteristic curves for predicting mortality at 3 months based upon listing MELD with and without listing serum sodium were 0.883 and 0.897, respectively, and at 6 months were 0.871 and 0.905, respectively. In conclusion, serum sodium < 126 mEq/L at listing or while listed for transplantation is a strong independent predictor of mortality. Addition of serum sodium to MELD increases the ability to predict 3‐ and 6‐month mortality in patients with cirrhosis. (HEPATOLOGY 2005;41:32–39.)

[1]  V. Arroyo,et al.  Prognostic value of spontaneous hyponatremia in cirrhosis with ascites , 1976, The American Journal of Digestive Diseases.

[2]  W. Jiménez,et al.  Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. , 1993, Gastroenterology.

[3]  R. Groszmann,et al.  Vasodilatation and sodium retention in prehepatic portal hypertension. , 1992, Gastroenterology.

[4]  A. Gerbes,et al.  Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. , 2003, Gastroenterology.

[5]  L. Martín-Herrera,et al.  Dilutional hyponatremia in patients with cirrhosis and ascites. , 2002, Archives of internal medicine.

[6]  B. Runyon.  Management of adult patients with ascites due to cirrhosis , 2004, Hepatology.

[7]  J. Kleinerman,et al.  RENAL FAILURE IN PATIENTS WITH CIRRHOSIS OF THE LIVER. I. CLINICAL AND PATHOLOGIC CHARACTERISTICS. , 1965, The American journal of medicine.

[8]  P. Thuluvath,et al.  A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo‐controlled trial , 2003, Hepatology.

[9]  M. Sherman,et al.  Transjugular Intrahepatic Portosystemic Stent Shunt: Effects on Hemodynamics and Sodium Homeostasis in Cirrhosis and Refractory Ascites , 1995, Annals of Internal Medicine.

[10]  T. Therneau,et al.  A model to predict survival in patients with end‐stage liver disease , 2001 .

[11]  M McCarthy,et al.  Hepatology , 1999, Rapid Medicine.

[12]  R. Schrier,et al.  Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis. , 2001, Seminars in nephrology.

[13]  A. Mihas,et al.  Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. , 2003, Gastroenterology.

[14]  R. Wiesner,et al.  Model for end-stage liver disease (MELD) and allocation of donor livers. , 2003, Gastroenterology.

[15]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[16]  W. Jiménez,et al.  Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. , 1992, Gastroenterology.

[17]  R. Wiesner,et al.  The new liver allocation system: Moving toward evidence‐based transplantation policy , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[18]  J. Llach,et al.  Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. , 1988, Gastroenterology.

[19]  R. Schrier,et al.  New classification with prognostic value in cirrhotic patients. , 1989, Mineral and electrolyte metabolism.

[20]  C. Sanders,et al.  The effect of changing serum osmolality on the release of antidiuretic hormone in certain patients with decompensated cirrhosis of the liver and low serum osmolality. , 1959, The Journal of clinical investigation.

[21]  M. Lucey,et al.  Organ allocation: model for end-stage liver disease, Child-Turcotte-Pugh, Mayo risk score, or something else. , 2003, Clinics in liver disease.

[22]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[23]  R. Bataller,et al.  A prognostic model for predicting survival in cirrhosis with ascites. , 2001, Journal of hepatology.

[24]  A. Maggi,et al.  Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[25]  V. Arroyo,et al.  Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. , 2003, Journal of hepatology.

[26]  P. Kamath,et al.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts , 2000, Hepatology.